← back to search

Yongkun Sun

Xinxiang Medical University · CN
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Gastric Cancer Management and Outcomes, Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies, and Pancreatic and Hepatic Oncology Research.
h-index
22
citations
2,450
works
137
NIH funding
primary concept
Medicine
email

Recent publications

Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China
BMC Cancer 2024cited by 9position: middledoi
Treatment modalities of regorafenib and survival in metastatic colorectal (mCRC) patients: A real-world multicenter retrospective study.
Journal of Clinical Oncology 2023cited by 1position: middledoi
Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements
Liver Cancer 2022cited by 70position: firstdoi
Clinical characteristics, medical service utilization, and expenditure for colorectal cancer in China, 2005 to 2014: Overall design and results from a multicenter retrospective epidemiologic survey
Cancer 2021cited by 106position: middledoi
Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703)
The Oncologist 2021cited by 63position: middledoi
Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey
HPB 2021cited by 6position: middledoi
Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma
Clinical Cancer Research 2018cited by 327position: middledoi
Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer
Thyroid 2018cited by 112position: firstdoi
Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
Journal of Hematology & Oncology 2016cited by 426position: firstdoi
Phase II study of anlotinib for treatment of advanced soft tissues sarcomas.
Journal of Clinical Oncology 2016cited by 23position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Yihebali Chi · Chinese Academy of Medical Sciences & Peking Union Medical College4 papers (2016–2018)Jinwan Wang · Baoji City Central Hospital3 papers (2016–2018)Feng Du · Ministry of Education3 papers (2016–2018)Xiaohui Niu · King University2 papers (2016–2018)Ping Sun · Guizhou University2 papers (2016–2018)Guofan Qu · Harbin Medical University2 papers (2016–2018)Jianchun Yu · Chinese Academy of Medical Sciences & Peking Union Medical College2 papers (2016–2018)Shengmian Li · Hebei Medical University2 papers (2023–2024)Yunbo Zhao · Weifang Medical University2 papers (2023–2024)Zhiyong He · Central South University2 papers (2016–2018)Shusen Wang · Nanjing Medical University2 papers (2016–2018) · 2 papers (2016–2018)Yongkui Lu · Guangxi Medical University2 papers (2016–2018)Qiong Wu · Union Hospital2 papers (2016–2018)Guowen Wang · Anhui Medical University2 papers (2016–2018)Liangjun Zhu · Nanjing Medical University2 papers (2023–2024)Zhiwei Fang · Ministry of Education2 papers (2016–2018)Xiaonan Hong · Fudan University Shanghai Cancer Center2 papers (2016–2018) · 2 papers (2016–2018) · 2 papers (2023–2024)